| Name of study |
Rotterdam study, targeting cardiovascular, endocrine, hepatic, neurological, ophthalmic, psychiatric, dermatological, oncological and respiratory diseases |
| Inclusion criteria |
Community dwelling population aged 45/55 years and older in Rotterdam, no diabetes at baseline |
| Exclusion criteria |
No valid baseline fasting glucose measurement, no informed consent |
| Notes |
Baseline data for prediabetic cohort (N = 1382) |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Study participation: description of source population or population of interest |
Low risk |
Yes |
| Study participation: description of glycaemic status at baseline |
Low risk |
Yes |
| Study participation: adequate description of sampling frame & recruitment |
Low risk |
Yes |
| Study participation: adequate description of period & recruitment place |
Low risk |
Yes |
| Study participation: adequate description of inclusion & exclusion criteria |
Low risk |
Inclusion and exclusion criteria described |
| Study attrition: description of attempts to collect information on participants who dropped out |
Unclear risk |
Not reported |
| Study attrition: reasons for loss to follow‐up provided |
Unclear risk |
Not reported |
| Study attrition: adequate description of participants lost to follow‐up |
Unclear risk |
Not reported |
| Study attrition: no important differences between participants who completed the study and those who did not |
Unclear risk |
Not reported |
| Glycaemic status measurement: provision of clear definition or description of glycaemic status |
Low risk |
Yes |
| Glycaemic status measurement: valid and reliable method of glycaemic status measurement |
Low risk |
Yes |
| Glycaemic status measurement: continuous variables reported or appropriate cut points used |
Low risk |
FBG > 6.0 and < 7.0; non‐fasting BG > 7.7 and < 11.1 |
| Glycaemic status measurement: same method and setting of measurement of the glycaemic status for all study participants |
Low risk |
Yes |
| Outcome measurement: clear definition of the outcome provided |
Low risk |
FBG ≥ 7.0; non‐fasting BG ≥ 11.1; antihyperglycaemic medication |
| Outcome measurement: method of outcome measurement used valid & reliable |
Low risk |
Yes |
| Outcome measurement: same method & setting of outcome measurement for all study participants |
Low risk |
Yes |
| Study confounding: important confounders measured |
Unclear risk |
Some covariates for lifetime risk of diabetes (see Appendix 16 and Appendix 17) |
| Study confounding: clear definitions of important confounders provided |
Low risk |
Yes |
| Study confounding: measurement of confounders valid & reliable |
Low risk |
Yes |
| Study confounding: same method & setting for measurements of confounders for all study participants |
Unclear risk |
Yes |
| Study confounding: appropriate methods used if missing confounder data imputed |
Unclear risk |
Not reported |
| Study confounding: important potential confounders accounted for in study design |
Unclear risk |
For lifetime risk of diabetes |
| Study confounding: important potential confounders accounted for in the analysis |
Unclear risk |
For lifetime risk of diabetes |
| Statistical analysis & reporting: sufficient presentation of data to assess adequacy of the analytic strategy |
Low risk |
Incidence rate |
| Statistical analysis & reporting: the statistical model is adequate for the design of the study |
Unclear risk |
Modified version of survival analysis to calculate the lifetime risk of diabetes |
